Researchers based at the University of Toronto (ON, CA) have developed a microfluidic device that could be used to separate malignant plasma cells from healthy red blood cells. The device could have the potential to detect and monitor blood cancer.
A recent study reports a new biomarker panel, comprised of 28 physical and molecule measures, that could successfully confirm the diagnosis of warzone-related post-traumatic stress disorder (PTSD) with 77% accuracy.
A prototype wearable device has been developed to continuously collect live cancer cells directly from a patient’s blood, presenting an alternative to biopsies.
Researchers from King Saud University (Riyadh, Saudi Arabia) have developed a new ELISA technique, with increased sensitivity and selectivity, for the simple monitoring of bevacizumab levels in blood plasma.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
Novel technology, using single-color digital PCR, could enable the detection of cancerous DNA in circulating blood.
Development of blood monitoring technology that could measure lactate levels in patients experiencing shock
Panicos Kyriacou, a professor at City, University of London, UK, is leading the design and development of a novel optical sensor for the continuous monitoring of lactate in blood.
A blood test could predict how men diagnosed with advanced prostate cancer respond to targeted disease treatments.
PerkinElmer have developed a new immunoassay that can reliably screen for Duchenne muscular dystrophy in new born infants.
Prospective clinical trial results demonstrate that a biomarker blood test could detect lung cancer recurrence on average 6 months earlier than CT scans.